Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials

Br J Cancer. 2018 Mar 20;118(6):763-769. doi: 10.1038/bjc.2017.480. Epub 2018 Feb 20.

Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • CTLA-4 Antigen / antagonists & inhibitors
  • Clinical Trials, Phase I as Topic / methods*
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Prognosis
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Risk Assessment
  • Severity of Illness Index
  • Young Adult

Substances

  • CTLA-4 Antigen
  • CTLA4 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor